Summary of Key Points
Shangwei New Materials has been a “star stock” in this round of robotics market gains, with its share price increasing by more than 30 times in half a year. However, the company’s performance in the first half of 2026 shifted from profit to loss, and the second-quarter deficit even widened. The reason is that the company invested over 90% of its research and development (R&D) expenses in the consumer-grade embodied intelligent robotics business, which has not yet generated any revenue. Additionally, the company’s equity incentive plan focuses solely on revenue growth from the robotics business (aiming for a 7-fold increase by 2028 compared to 2026), as well as the number of patents and R&D investment, without considering profits at all. The goals are ambitious but full of uncertainties.
Detailed Analysis
The Contradictory Situation of Stock Price and Performance: Betting on the Future vs. Burning Current Resources
Shangwei New Materials’ share price has skyrocketed by 31 times, driven by market expectations for “consumer-grade embodied intelligent robots.” These robots are seen as the next generation of smart devices, supported by national planning, advancements in AI technology, and decreasing costs, which make them promising. In reality, the company suffered a loss of 166 million yuan in the first half of the year, reversing its profits from the same period last year.
Why such a contrast? The robotics business is still in the “money-consuming” phase: R&D expenses for the first half amounted to 180 million yuan, of which 164 million yuan were spent on robotics (91% of total R&D). This, combined with recruitment, material purchases, and equipment depreciation, completely eroded the company’s profits. The only profitable business is the “new materials” segment, but it cannot offset the significant losses from the robotics division.
Robotic R&D: Heavy Investment, Yet Not at the “Monetization” Stage
The company has invested heavily in robotics, with 164 million yuan in R&D (22% of revenue, compared to just 2.7% last year). However, its two robotic products—“Qiyuan Q1” (humanoid) and “Qiyuan T1” (transformable)—are still in the demonstration phase. Q1 was unveiled at the end of last year, and T1 made its debut at an AI conference in July this year; neither has been mass-produced or sold yet.
The only “good news” is that the company received 210 million yuan in advance payments for robots, but these cannot be considered revenue until the products are delivered. This indicates that buyers are willing to pay in advance, but whether the products can be delivered on time and without issues remains uncertain.
Equity Incentive Plan: Focusing Only on Revenue, Not Profit
The company’s equity incentive plan is highly focused on the robotics business, requiring a 7-fold increase in robotics revenue by 2028 (meaning at least 500 million yuan in 2026 should lead to 4 billion yuan in 2028), along with obtaining numerous patents and continuing to increase R&D investment. Profits are not part of the evaluation criteria. The reason for this approach is that the company realizes it won’t make money from the robotics business immediately, so it aims to first build scale by using equity incentives to motivate employees to boost sales. However, the goal of a 7-fold increase in two years is extremely ambitious and uncertain.
Cash Flow: The Old Business Provides Stability, but Advance Payments Offer Some Comfort
The only positive aspect of the semi-annual report is the net operating cash flow of 208 million yuan, a 41% year-over-year increase. This money comes mainly from two sources: steady sales of the new materials business and advance payments received for the robotics products.
This suggests that the company won’t face immediate financial shortages, but the issue is that these advance payments are not actual revenue. If the robotic products cannot be delivered on time or if customers request refunds due to dissatisfaction, the company may have to return the money.
Future Risks: From Demonstration to Profitability, Every Step Is a Challenge
Shangwei New Materials’ valuation relies entirely on the “future potential” of its robotics business. However, several hurdles must be overcome:
- Can the products be mass-produced? Currently, they are only in the demonstration stage, and large-scale production requires a verified supply chain, capacity, and quality control.
- Can revenue meet the targets? The 7-fold growth target set by the equity incentive plan is very aggressive. If the market doesn’t respond positively or competitors gain market share, the goals could be unachievable.
- When will profitability be achieved? With such high R&D expenses, even if revenue increases, profits may still be negative due to the early stage of the robotics industry and fierce competition.
If these challenges cannot be overcome, the stock price’s “bubble” might burst.
In Summary
Shangwei New Materials is currently “betting on the future of robotics with current losses.” Its share price has risen significantly, but whether it can turn this dream into reality depends on whether its products can be sold and whether revenue targets are met. After all, in the end, real performance will determine the success of such speculation.
(End of translation)